Pharmaceutical composition for treating retinal dystrophies, comprising Nkx3.2 and fragment thereof as active ingredients

A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 18. Apr. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

KIM DAE-WON [VerfasserIn]
YUM YOUNG-NA [VerfasserIn]
RYU HEUI-YOUNG [VerfasserIn]
JEONG DA-UN [VerfasserIn]
CHOI SEUNG-WON [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-04-18, Last update posted on www.tib.eu: 2023-06-22, Last updated: 2023-06-30

Patentnummer:

US11628203

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA016946227